On September 22, Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics, agreed to plead guilty to two counts of violating the Federal Food, Drug, and Cosmetic (FD&C) Act related to the company’s introduction of misbranded Juxtapid (lomitapide). Along with the guilty pleas, Aegerion agreed to […]
Sep 28, 2017
By Jessica Hoerman
Juxtapid
